Menu

Markets

Research

News

Learn
Paper trading
AI Chat
Get the app WatchlistsPortfoliosAlerts
Sign in

Prime Medicine, Inc. PRME

Set alert

Price alert · PRME

All alert types
4.61 USD +0.17 +3.72%

As of Nov 3, 11:34 AM ET

Bid
4.61 × 3
Ask
4.62 × 10
4.50 Day range 4.89
2.67 52-week range 5.91
YTD
+32.71%
1 year
+0.99%
Open
4.50
Prev close
4.44
Mkt cap
836.15M
Vol
1.35M
Avg vol
4.05M
EPS
-1.07
P/E
0.00
Div yield
0.00%
More statistics
Low
4.50
High
4.89
Forward P/E
-3.96
Beta
2.67
Short ratio
5.85
Inst. own
44.38%
Dividend
0.00
Ex-div date
50-d avg
4.61
200-d avg
2.96
1y target
6.50

MAX chart

Chart tools
Interval
1m5m15m30m

Events in this range
  • May 19, 2025Rating: Chardan Capital · Buy → Buy
  • May 20, 2025Downgrade: HC Wainwright & Co. · Buy → Neutral
  • May 20, 2025Downgrade: JP Morgan · Overweight → Neutral
  • May 20, 2025Rating: JMP Securities · Market Outperform → Market Outperform
  • May 27, 2025Downgrade: Citigroup · Buy → Neutral
  • Aug 8, 2025Rating: Chardan Capital · Buy → Buy
Signals (69)
NameDateAgo
SMA: BullishOct 5, 20264 weeks ago
SMA: BullishOct 5, 20264 weeks ago
MACD: Buy SignalOct 5, 20264 weeks ago
MACD: Sell SignalSep 21, 20261 month ago
SMA: BearishSep 7, 20261 month ago
SMA: BearishSep 7, 20261 month ago
SMA: BullishAug 24, 20262 months ago
SMA: BullishAug 17, 20262 months ago
MACD: Buy SignalAug 17, 20262 months ago
MACD: Sell SignalJul 27, 20263 months ago
SMA: BearishJul 13, 20263 months ago
SMA: BearishJul 13, 20263 months ago
SMA: BullishJun 29, 20264 months ago
MACD: Buy SignalJun 29, 20264 months ago
SMA: BullishJun 22, 20264 months ago
SMA: BearishJun 1, 20265 months ago
SMA: BullishMay 25, 20265 months ago
SMA: BearishApr 27, 20266 months ago
SMA: BullishApr 13, 20266 months ago
SMA: BearishMar 9, 20267 months ago

Newest 20 of 69.

Analyst view

Consensus: buy

Buy
Price target (mean) 6.50 +41.2% upside
Target (low)
4.00
Target (mean)
6.50
Target (high)
10.00
Ratings (0m) 11 7 buy · 4 hold · 0 sell
  • Strong buy1
  • Buy6
  • Hold4
  • Sell0
  • Strong sell0

Recommendation trend

  • This month 11
  • 1 month ago 11
  • 2 months ago 12
  • 3 months ago 12

Earnings and revenue estimates

Consensus for the coming quarters and fiscal years

PRME analyst estimates
PeriodEPS estimateLow – highYear agoEPS growthRevenue estimateRevenue growthAnalysts
Current quarter-0.24724-0.33 – -0.21-0.44+43.8%2.80M+1240.1%10
Next quarter-0.2003-0.34 – -0.11-0.31+35.4%3.77M+72.6%10
Current year-1.17-1.45 – -1.06-1.65+29.3%8.73M+192.5%11
Next year-0.8659-1.51 – -0.56-1.17+25.8%24.36M+179.1%9

Upgrades and downgrades

The latest rating changes

PRME analyst upgrades and downgrades
DateFirmActionFromTo
Aug 8, 2025Chardan CapitalMaintainedBuyBuy
May 27, 2025CitigroupDowngradeBuyNeutral
May 20, 2025JMP SecuritiesMaintainedMarket OutperformMarket Outperform
May 20, 2025JP MorganDowngradeOverweightNeutral
May 20, 2025HC Wainwright & Co.DowngradeBuyNeutral
May 19, 2025Chardan CapitalMaintainedBuyBuy
Mar 20, 2025Chardan CapitalMaintainedBuyBuy
Mar 19, 2025HC Wainwright & Co.ReiteratedBuyBuy
Mar 4, 2025Citizens Capital MarketsReiteratedMarket OutperformMarket Outperform
Mar 3, 2025HC Wainwright & Co.ReiteratedBuyBuy
Mar 3, 2025Chardan CapitalMaintainedBuyBuy
Dec 10, 2024JMP SecuritiesInitiated—Market Outperform
Dec 3, 2024GuggenheimReiteratedBuyBuy
Oct 25, 2024HC Wainwright & Co.ReiteratedBuyBuy
Aug 9, 2024HC Wainwright & Co.ReiteratedBuyBuy
May 20, 2024HC Wainwright & Co.Initiated—Buy
May 16, 2024CitigroupUpgradeNeutralBuy
May 13, 2024JP MorganMaintainedOverweightOverweight
Apr 23, 2024WedbushReiteratedOutperformOutperform
Apr 22, 2024Chardan CapitalInitiated—Buy
Apr 8, 2024TD CowenInitiated—Buy
Apr 3, 2024WedbushInitiated—Outperform
Apr 2, 2024WedbushInitiated—Outperform
Mar 8, 2024JP MorganMaintainedOverweightOverweight
Mar 5, 2024GuggenheimMaintainedBuyBuy
Dec 8, 2023CitigroupInitiated—Neutral
Nov 7, 2023JP MorganMaintainedOverweightOverweight
Oct 9, 2023BMO CapitalInitiated—Outperform
Sep 6, 2023JonesTradingInitiated—Buy
Aug 14, 2023Morgan StanleyMaintainedEqual-WeightEqual-Weight